A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

(2016) Viktoria Moschetti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Decreased levels of guanosine 3′, 5′-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

(2015) Ana Ugarte et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

(2014) J. C. Morris et al.   JOURNAL OF INTERNAL MEDICINE

Humanistic burden in schizophrenia: A literature review

(2014) A. Millier et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease

(2012) Ana García-Osta et al.   ACS Chemical Neuroscience

Cognitive Impairment Associated with Schizophrenia: A Review of the Humanistic Burden

(2012) Helen Kitchen et al.   ADVANCES IN THERAPY

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

(2011) Salvatore Salomone et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?

(2011) Richard S. E. Keefe et al.   SCHIZOPHRENIA BULLETIN

Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents

(2010) Christopher Schmidt   CURRENT TOPICS IN MEDICINAL CHEMISTRY

PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers

(2009) Timothy Nicholas et al.   Alzheimers & Dementia

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

(2008) Olga A. H. Reneerkens et al.   PSYCHOPHARMACOLOGY